

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7264859

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANGELA ZAMPELLA	02/24/2022
STEFANO FIORUCCI	02/24/2022
RECEIVING PARTY DATA	
Name:	BAR PHARMACEUTICALS SOCIETA' A RESPONSABILITA' LIMITATA
Street Address:	VIA SICILIA, 2,
City:	REGGIO EMILIA,
State/Country:	ITALY
Postal Code:	42124
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17260596
CORRESPONDENCE DATA	
Fax Number:	(212)609-6821
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-609-6800
Email:	lyoung@mccarter.com
Correspondent Name:	MCCARTER & ENGLISH, LLP
Address Line 1:	WORLDWIDE PLAZA
Address Line 2:	825 EIGHTH AVENUE
Address Line 4:	NEW YORK, NEW YORK 10019
ATTORNEY DOCKET NUMBER:	129012-00401
NAME OF SUBMITTER:	KATHLEEN N. EHRHARD
SIGNATURE:	/Kathleen N. Ehrhard/
DATE SIGNED:	04/06/2022
Total Attachments: 2	
source=ExecutedAssignment#page1.tif	
source=ExecutedAssignment#page2.tif	

ASSIGNMENT

WHEREAS, WE , **Angela ZAMPELLA** and **Stefano FIORUCCI**, hereinafter called Assignor, have invented certain improvements in

ISOXAZOLE AS FXR RECEPTOR AGONISTS

which was filed as an application for a United States Letters Patent on **January 15, 2021** and assigned application serial number **17/260,596** and based upon international application number **PCT/IB2019/056114**, which was filed on **July 17, 2019** and which designates the United States and;

WHEREAS, **BAR PHARMACEUTICALS SOCIETA' A RESPONSABILITA' LIMITATA**, a corporation organized under the laws of Italy, having its principal office at Via Sicilia, 2, Reggio Emilia, Italy 42124 (hereinafter "Assignee"), desires to acquire the entire right, title, and interest in the invention, and to any patents to be obtained therefor;

Now therefore, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

WE, the above named Assignor, hereby sell, assign and transfer to the above named Assignee, its successors and assigns, any and all interest WE have or may have in said invention or improvement, for the United States of America and all foreign countries, including all rights of priority under the International Convention for the Protection of Industrial Property in said invention or improvement in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said utility application, any utility application claiming the benefit of the filing date of or priority to said application, and/or any divisional, continuation, reissue, re-examination, or other applications based in whole or in part thereon. And WE agree, for ourselves and our executors and administrators, with said Assignee and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, Oath or Declaration, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Assignee,

with specifications and claims in such form as shall be approved by the counsel of said Assignee and to vest and confirm in said Assignee, its successors and assigns, the legal title to all such patents.

And WE do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Assignee, its successors and assigns.

By Angela Zampella
Angela ZAMPELLA

Date: February 24, 2022

By: Stefano Fiorucci
Stefano FIORUCCI

Date: February 24, 2022